



| | | | |
|-------------------|-----------------------|----------------|-------------------------------------|
| Name | : Mr.PANKAJ GUPTA | Centre Details | : HOMETRAIL BUILDTECH PRIVATE LIMIT |
| Age | : 54 Yrs Sex: Male | Accession. ID | : OQG2303310412 |
| Collection Date | : 30/Mar/2023 12:00PM | Referred By | : DR.SACHIN GUPTA |
| Received Date | : 03/Apr/2023 11:06AM | Report Date | : 03/Apr/2023 01:01PM |
| Registration Date | : 31/Mar/2023 | Ref. No. | : |

DEPARTMENT OF FLOW CYTOMETRY

Flowcytometry-Acute Leukemia MRD Panel

MRD Analysis done by Flow Cytometry

Markers used are CD7, CD13, CD15, CD19, CD33, CD34, CD38, CD45, CD117, CD123, HLADR in 8 colour panel in various combinations

CLINICAL DETAILS: AML on treatment.

Previous Immunophenotype: AML

Sample time point: Not known

SPECIMEN: Bone marrow sample showed TLC = 10,000 cells/ μ l.

FLOW CYTOMETRY ANALYSIS:

Instrument / Software: BD FACS Canto / BD FACS DIVA

Gating Strategy: 8-colour Flow Cytometry using forward-side scatter and CD45-side scatter analysis.

Cell Preparation Method: Lyse - Wash - Stain - Wash

Gating strategy: SSC Vs CD45 and FSC Vs SSC

Total events acquired = 20,00,000 cells / tube

CD34 = 46.8%

AML residual blasts = 69.2% of all Leukocytes (Expressing CD7, CD13, CD33, CD34, CD38 Dim, CD117)

IMPRESSION: AML MRD = 69.2%

Note :- As per ELN 2018 recommendation, AML MRD threshold for clinical significance is considered to be $\geq 0.1\%$

Please correlate with previous hematological, immunophenotypic reports, detailed clinical/ancillary inputs and exact day of chemotherapy. LOQ of the assay is ≥ 30 events.

Comment: *First pull bone marrow aspirate is recommended sample for MRD testing as subsequent pulls may show hemodilution.*

Flow cytometric detection (FCM) of MRD is based on detection of abnormal population compared to normal maturation pattern and the identification of immunophenotypic combinations expressed on leukemic cells but not on normal



Dr. Shivali Ahlawat
MD. D.N.B (Path)
Lab Director- National Reference Lab
HMC RG-No.17038



| | | | |
|-------------------|-----------------------|----------------|-------------------------------------|
| Name | : Mr.PANKAJ GUPTA | Centre Details | : HOMETRAIL BUILDTECH PRIVATE LIMIT |
| Age | : 54 Yrs Sex: Male | Accession.ID | : OQG2303310412 |
| Collection Date | : 30/Mar/2023 12:00PM | Referred By | : DR.SACHIN GUPTA |
| Received Date | : 03/Apr/2023 11:06AM | Report Date | : 03/Apr/2023 01:01PM |
| Registration Date | : 31/Mar/2023 | Ref. No. | : |

DEPARTMENT OF FLOW CYTOMETRY

hematopoietic cells-leukemia associated immunophenotypes (LAIPs).

FCM has emerged as the most promising methods for detecting submicroscopic levels of leukemia. Prospective studies in large series of patients have demonstrated a strong correlation between MRD levels during clinical remission and treatment outcome. Therefore, MRD assays can be reliably used to assess early response to treatment and predict relapse.

Various groups have different thresholds for AML MRD detection, most lying between 0.01-1%, as it is technically more challenging due to heterogenous blast population and unstable phenotypes. A positive MRD result indicates an increased risk of relapse for the patient.

This test has been developed and its performance characteristics determined by Oncquest Laboratories.

Note: All investigations have their limitations which are imposed by the limits of sensitivity and specificity of individual assay procedures as well as the quality of the specimen received by Oncquest. Isolated laboratory investigations never confirm the final diagnosis of the disease. They only help in arriving at a diagnosis in conjunction with clinical presentation and other related investigations.

*** End Of Report ***

| |
|--|
| Disclaimer: All Results released pertain to the specimen submitted to the lab |
| 1. Test results are dependent on the quality of the sample received by the lab |
| 2. Tests are performed as per schedule given in the test listing and in any unforeseen circumstances, report delivery may be delayed |
| 3. Test results may show interlaboratory variations |
| 4. All dispute and claims are subjected to local jurisdiction only |
| 5. Test results are not valid for medico legal purposes |
| 6. For all queries, feedbacks, suggestions, and complaints, please contact customer care support +0124 665 0000 |



Dr. Shivali Ahlawat
MD. D.N.B (Path)
Lab Director- National Reference Lab
HMC RG-No.17038

Please correlate the test results with clinical history of the patient. Not for medico-legal purpose.

Verify this report by scanning the QR code on top. In case of any discrepancy please report to +0124 665 0000

This sample is processed at **Oncquest Laboratories Ltd.; A-17 Infocity, Sector-34, Gurugram.**